BioMarin Pharmaceuticals
BMRN
531 hedge funds and large institutions have $14.7B invested in BioMarin Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 185 increasing their positions, 181 reducing their positions, and 52 closing their positions.
9% more capital invested
Capital invested by funds: $13.5B → $14.7B (+$1.27B)
4% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 52
2% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 181
0% more funds holding
Funds holding: 531 → 531 (0)
1.43% less ownership
Funds ownership: 98.04% → 96.61% (-1.4%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
37% less call options, than puts
Call options by funds: $111M | Put options by funds: $177M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$178M |
| 2 |
JP Morgan Chase
New York
|
+$72.9M |
| 3 |
California Public Employees Retirement System
Sacramento,
California
|
+$29.6M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$25.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$18.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$82.4M |
| 2 |
BlackRock
New York
|
-$82.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$53.4M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$44M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$34.9M |
BMRN Hedge Fund Activity: Q2 2021 in Review
531 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2021, worth a combined $14.7B — up 9.4% from $13.5B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new BMRN positions and 52 closed out — a net gain of 2 holders — while 185 added to existing stakes and 181 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $178M. The largest seller was Janus Henderson Group, cutting an estimated $82.4M.
- 531 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $14.7B of BioMarin Pharmaceuticals stock for Q2 2021, up 9.4% quarter-over-quarter.
- 54 funds opened new BioMarin Pharmaceuticals positions in Q2 2021 and 52 closed out, a net change of +2 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2021 was Dodge & Cox, an estimated $178M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2021 was Janus Henderson Group, an estimated $82.4M sold.
Based on aggregated 13F filings for Q2 2021.